Loading...
Market
Story
Pfizer's RSV Vaccine Abrysvo Shows Positive Results in Study
Aug 12, 2024, 10:48 AM
Pfizer announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has shown positive results in a late-stage study involving immunocompromised adults. The study demonstrated that Abrysvo generated a strong immune response across four groups of adults. This development marks a significant step for Pfizer as it seeks to expand its vaccine offerings and address the needs of vulnerable populations.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Less than 1 million • 25%
1-3 million • 25%
3-5 million • 25%
More than 5 million • 25%
Yes • 50%
No • 50%
Less than 1 million • 25%
1 million to 3 million • 25%
3 million to 5 million • 25%
More than 5 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Yes • 50%
No • 50%
Decrease by less than 10% • 25%
Decrease by 10% to 20% • 25%
Decrease by 20% to 30% • 25%
Decrease by more than 30% • 25%